bluuebunny/crossref_metadata_2025_split huggingface dataset:
Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study
Authors: Cortes Jorge , Moore Joseph O. , Maziarz Richard T. , Wetzler Meir , Craig Michael , Matous Jeffrey , Luger Selina , Dey Bimalangshu R. , Schiller Gary J. , Pham Dat , Abboud Camille N. , Krishnamurthy Muthuswamy , Brown Archie , Laadem Abderrahmane , Seiter Karen 
Published: August 2010

Purpose Rasburicase is effective in controlling plasma uric acid in pediatric patients with hematologic malignancies. This study in adults evaluated safety of and compared efficacy of rasburicase alone with rasburicase followed by oral allopurinol and with allopurinol alone in controlling plasma uric acid. Patients and Methods Adults with hematologic malignancies at risk for hyperuricemia and tumor lysis syndrome (TLS) were randomly assigned to rasburicase (0.20 mg/kg/d intravenously days 1-5), rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d days 1 to 3 followed by oral allopurinol 300 mg/d days 3 to 5), or allopurinol (300 mg/d orally days 1 to 5). Primary efficacy variable was plasma uric acid response rate defined as percentage of patients achieving or maintaining plasma uric acid ≤ 7.5 mg/dL during days 3 to 7. Results Ninety-two patients received rasburicase, 92 rasburicase plus allopurinol, and 91 allopurinol. Plasma uric acid response rate was 87% with rasburicase, 78% with rasburicase plus allopurinol, and 66% with allopurinol. It was significantly greater for rasburicase than for allopurinol (P = .001) in the overall study population, in patients at high risk for TLS (89% v 68%; P = .012), and in those with baseline hyperuricemia (90% v 53%; P = .015). Time to plasma uric acid control in hyperuricemic patients was 4 hours for rasburicase, 4 hours for rasburicase plus allopurinol, and 27 hours for allopurinol. Conclusion In adults with hyperuricemia or at high risk for TLS, rasburicase provided control of plasma uric acid more rapidly than allopurinol. Rasburicase was well tolerated as a single agent and in sequential combination with allopurinol.
Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy
Authors: Phan Jack , Mazloom Ali , Jeffrey Medeiros L. , Zreik Tony G. , Wogan Christine , Shihadeh Ferial , Rodriguez Maria Alma , Fayad Luis , Fowler Nathan , Reed Valerie , Horace Patrecia , Dabaja Bouthaina Shbib 
Published: August 2010

Purpose The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The role of consolidative radiation therapy (RT) in the setting of R-CHOP chemotherapy is not well reported. This retrospective analysis is an attempt to clarify this role. Patients and Methods Subjects were 469 patients with histologically confirmed DLBCL treated between January 2001 and December 2007. Variables including age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs) on positron emission tomography (PET), International Prognostic Index (IPI), and Ki67 staining (proliferation). Results Of 469 patients, 190 (40.5%) had stage I or II disease and 279 (59.5%) had stage III or IV disease, 327 (70%) had at least six cycles of R-CHOP, and 142 (30.2%) had involved-field RT (dose, 30 to 39.6 Gy) after complete response to chemotherapy. Median follow-up was 36 months (range, 8 to 85 months). Multivariate analysis showed that RT (P < .0001), IPI score (P = .001), response to therapy (P = .001), use of six to eight cycles of R-CHOP (P < .001), and combined presence (P = .006) or absence (P = .025) of high Ki67, high PET SUV, and bulky disease influenced overall survival (OS) and progression-free survival (PFS). Matched-pair analyses of patients who received six to eight cycles of R-CHOP with stage I or II disease (44 pairs) and all stages (74 pairs) indicated that RT improved OS (hazard ratio [HR], 0.52 and 0.29, respectively) and PFS (HR, 0.45 and 0.24, respectively) compared with no RT. Conclusion This study showed significant improvements in OS and PFS among patients who received consolidation RT after R-CHOP chemotherapy for DLBCL.
Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
Authors: Drake Matthew T. , Maurer Matthew J. , Link Brian K. , Habermann Thomas M. , Ansell Stephen M. , Micallef Ivana N. , Kelly Jennifer L. , Macon William R. , Nowakowski Grzegorz S. , Inwards David J. , Johnston Patrick B. , Singh Ravinder J. , Allmer Cristine , Slager Susan L. , Weiner George J. , Witzig Thomas E. , Cerhan James R. 
Published: August 2010

Purpose Vitamin D insufficiency is common in the United States, with low levels linked in some studies to higher cancer incidence, including non-Hodgkin's lymphoma (NHL). Recent data also suggest that vitamin D insufficiency is related to inferior prognosis in some cancers, although there are no data for NHL. Patients and Methods We tested the hypothesis that circulating 25-hydroxyvitamin D [25(OH)D] levels are predictive of event-free survival (EFS) and overall survival (OS) in a prospective cohort of 983 newly diagnosed patients with NHL. 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels were measured by liquid chromatography-tandem mass spectrometry. Results Mean age at diagnosis was 62 years (range, 19 to 94 years); 44% of patients had insufficient 25(OH)D levels (< 25 ng/mL) within 120 days of diagnosis. Median follow-up was 34.8 months; 404 events and 193 deaths (168 from lymphoma) occurred. After adjusting for known prognostic factors and treatment, 25(OH)D insufficient patients with diffuse large B-cell lymphoma (DLBCL) had inferior EFS (hazard ratio [HR], 1.41; 95% CI, 0.98 to 2.04) and OS (HR, 1.99; 95% CI, 1.27 to 3.13); 25(OH)D insufficient patients with T-cell lymphoma also had inferior EFS (HR, 1.94; 95% CI, 1.04 to 3.61) and OS (HR, 2.38; 95% CI, 1.04 to 5.41). There were no associations with EFS for the other NHL subtypes. Among patients with DLBCL and T-cell lymphoma, higher 1,25(OH)2D levels were associated with better EFS and OS, suggesting that any putative tumor 1-α-hydroxylase activity did not explain the 25(OH)D associations. Conclusion 25(OH)D insufficiency was associated with inferior EFS and OS in DLBCL and T-cell lymphoma. Whether normalizing vitamin D levels in these patients improves outcomes will require testing in future trials.
Original Document Needed to Safely Scan Orders to Pharmacy; Ketek's Unit-Dose Package Has Ambiguous Label; “Units” Not IU
Authors: Cohen Michael R. 
Published: August 2010

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program (MERP), which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below. Errors, close calls, or hazardous conditions may be reported through the ISMP ( www.ismp.org ) or USP ( www.usp.org ) Web sites or communicated directly to ISMP by calling 800-FAIL-SAFE or via E-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.
Citalopram: Fibromyalgia
Authors: Generali Joyce , Cada Dennis J. 
Published: August 2010

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form, so the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments regarding “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Abatacept
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: August 2010

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The FI.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2006 monograph topics are ibuprofen lysine, rasagiline, fentanyl iontophoretic transdermal system, quadrivalent human papillomavirus vaccine, and zoster vaccine. The DUE is on lubiprostone.
Adacel (Tdap) and Daptacel (DTaP) Confusion; Diastat AcuDial: Dial, Set, and Lock the Dose; Why the Abbreviation “PCN” Should Be Avoided
Authors: Cohen Michael R. 
Published: August 2010

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program (MERP), which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below. Errors, close calls, or hazardous conditions may be reported through the ISMP ( www.ismp.org ) or USP ( www.usp.org ) Web sites or communicated directly to ISMP by calling 800-FAIL-SAFE or via E-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.
Medication Prescribing Errors Involving the Route of Administration
Authors: Lesar Timothy S. 
Published: August 2010

Context Administration of medications by the wrong route or as a wrong dose for the ordered route presents significant risk for adverse drug events. Objective To quantify and identify the characteristics of prescribing errors involving the route of drug administration. Design Evaluation of medication orders with errors involving the route of administration detected by pharmacists in a 631-bed tertiary care teaching hospital over a 42-month period. Main Outcome Measures Type, frequency, characteristics, potential for adverse effects, contributors, and enabling factors of medication prescribing errors involving the route of administration. Results A total of 862 prescribing errors were detected. Sixty-one different types of route-related prescribing errors, involving 135 different medications, were detected. The most common type of these errors involved prescribing the wrong route of administration (39.2%) and prescribing the same or similar medications to be given concurrently by two routes (21.1 %). The most common class of medications involved were cardiovascular agents (23.5%). The most common medication characteristic identified as contributing to route-related prescribing errors was the common and routine use of a drug by multiple routes (75.9%). Conclusions Prescribing errors involving the route of administration are common, occur in a wide variety of ways, and involve a wide variety of medications. A number of commonly recommended medication safety practices should reduce risk to patients from route-related medication prescribing errors.
Meeting JCAHO Medication Management Standards: Getting Everyone Involved
Authors: Fogel Tina Psihogios , Todd Mark W. , Wilson Peggy C. , Como Jackson A. 
Published: August 2010

This continuing feature highlights the experiences of various health care organizations regarding the Joint Commission on Accreditation of Healthcare Organizations' (JCAHO) Medication Management Standards and National Patient Safety Goals implementation. Practical information on what worked and how organizations have been surveyed regarding the standards and goals will be provided along with updates on revisions and recommendations being established by JCAHO. To share your success stories, contact Sondra K. May, PharmD, Department of Pharmacy Services, University of Colorado Hospital, 4200 East Ninth Avenue, Box A-027, Denver, CO 80262. E-mail: sondra.may@uch.edu . Purpose Changes in the JCAHO survey process and in the scope of the standards governing medication management (MM) make it no longer possible to have the Pharmacy Department as the sole contact point for JCAHO questions pertaining to medication use. In an effort to raise awareness of MM standards to the institutional level, we conducted an exhaustive review of individual standards and communicated shared points of responsibility to persons outside the Pharmacy Department. Methods Organizational changes were implemented to direct our efforts. These included instituting an ad hoc Pharmacy Department Committee and creating a Coordinator for MM standards position. Hospital organizational structure changed, so the Pharmacy Director now reports directly to the Chief Operating Officer. A spreadsheet outlined each MM standard including existing policies, those requiring revision, and departmental or interdisciplinary actions needed. Other disciplines were involved as indicated in policy revisions and improvements in medication-use systems. A new process for holding other departments accountable for medications purchased and stored outside of Pharmacy was implemented. Staff education focused on key issues and standards. Mock surveys were regularly conducted. Results Policies were revised in collaboration with the Pharmacy and Therapeutics Committee and other interdisciplinary teams. Departments purchasing their own medications routinely inspect their stock. Pharmacy staff education became routine. Conclusions Through focused interdisciplinary efforts, our institution addressed potential deficiencies, improved medication safety and was better prepared for the JCAHO survey. The first unannounced survey was just completed. There were no Recommendations for Improvement (RFIs) regarding the MM standards.
The Relationship Between Internal Encoding Style and Obsessive–Compulsive Symptoms in a Subclinical Sample
Authors: Belayachi Sanaâ , Van der Linden Martial 
Published: August 2010

AbstractThis study examined the relationships between obsessive-compulsive symptoms (OCs) and encoding style in a subclinical sample, by using a questionnaire that evaluates the extent to which preexisting schemata (versus cues from the outside world) affect encoding processes (Lewicki, 2005). Research on encoding style has revealed on one hand the existence of individual differences in the tendency to impose interpretive schemata in the process of encoding, and on the other hand the fact that an extremely internal mode of encoding has been found to be related to an increased propensity to self-perpetuate preexisting schemata. Furthermore, internal encoding may contribute to the development of psychopathological symptoms, through the self-perpetuation of dysfunctional schemata. The results confirmed that OCs are connected with an internal encoding style; specific relationships between obsessive-compulsive disorder (OCD) dimensions and internal encoding style were also found. These results are discussed in terms of the role of encoding style in the perpetuation of OCs, and its relationship to the dysfunctional beliefs characterising OCD.
Do Socially Anxious Individuals Hold Positive Metacognitive Beliefs About Rumination?
Authors: Wong Quincy J.J. , Moulds Michelle L. 
Published: August 2010

AbstractThe Self-Regulatory Executive Function (S-REF) model of affective dysfunction (Wells & Matthews, 1994) suggests that metacognitive beliefs are important for initiating and maintaining repetitive thought processes in emotional disorders. Rumination is reported by socially anxious individuals, yet it is not known whether this group endorse positive beliefs about the utility of rumination. We predicted that higher levels of social anxiety would be positively associated with stronger positive metacognitive beliefs about rumination. In Study 1 (N= 250 undergraduates), a measure of social anxiety was positively correlated with a measure of positive metacognitive beliefs about rumination, even when controlling for gender and level of depression. Given this result, we then attempted to replicate the finding in another sample, as well as test whether positive metacognitive beliefs about rumination would mediate the relationship between social anxiety and trait rumination. In Study 2 (N= 124 undergraduates), a social anxiety composite measure was positively correlated with a measure of positive metacognitive beliefs about rumination, even when controlling for gender, level of depression and level of rumination. Positive metacognitive beliefs about rumination were also shown to partially mediate the relationship between social anxiety and trait rumination. These results support the S-REF model and provide a potential account of why socially anxious individuals engage in rumination. Implications for the treatment of social anxiety are discussed.
Evidence of Impaired Event-Based Prospective Memory in Clinical Obsessive–Compulsive Checking
Authors: Harris Lynne M. , Vaccaro Lisa , Jones Mairwen K. , Boots Georgina M. 
Published: August 2010

AbstractBased on findings from subclinical OCD checking samples (Cuttler & Graf, 2007; 2008), Cuttler and Graf (2009) suggested that checking may develop to compensate for prospective memory failures. The present study provides the first evidence of prospective memory problems in a clinical sample of OCD checkers (n = 26) compared to a group of healthy controls (n = 26). Consistent with earlier work with subclinical samples, the OCD checkers performed more poorly on an event-based, but not a time-based, prospective memory task. However, the OCD checkers did not report more subjective prospective memory failures than controls and their confidence in prospective memory accuracy was higher than that of controls. An explanation of the inconsistent findings with regard to metamemory in clinical and subclinical OCD checking is provided. Further research assessing both subjective memory performance and the strategies understood to support memory is needed to clarify the contribution of prospective memory to OCD checking.
Deliberate Self-Harm: The Interplay Between Attachment and Stress
Authors: Hallab Lisa , Covic Tanya 
Published: August 2010

AbstractThis study investigated the relationship between attachment, mood and deliberate self-harm (DSH) in a nonclinical population (n= 114). In addition to a range of risky behaviours, the most commonly reported DSH behaviours wereHead-banging(47%),Hitting(46%),Scratching(38%) andCutting(34%). Those who engaged in DSH had poorer quality of attachment to both parents but not peers, and higher levels of depression, anxiety and stress. Path analysis was then used to examine the interaction between attachment, mood and DSH. The impact of the quality of attachment on DSH was found to be mediated by stress, which suggests that DSH may be a maladaptive coping mechanism. Attachment to father and peers was found to be more influential than attachment to mother. Our findings suggest that DSH may be more prevalent in the community than previously recognised, and that attachment, which is currently neglected in DSH research, warrants further investigation in both clinical and nonclinical populations.
Laboratory Evaluation of Stone Matrix Asphalt Mixtures with Polyethylene and Cellulose Stabilizers
Authors: Punith V. S. , Raju Sridhar , Kumar. K Kantha , Bose Sunil , Veeraragavan A. 
Published: August 2010

Abstract
This paper deals with the viability of using reclaimed polyethylene (PE) derived from low-density PE carry bags in shredded form collected from domestic waste as stabilizing fibers to evaluate the performance of stone matrix asphalt (SMA). Conventional SMA mixtures were used as reference mixture and were prepared using 60/70-grade asphalt cement and cellulose fibers as stabilizer. The use of PE-modified binder (PEMB) was also investigated as stabilizer in SMA mixtures. The performance of these mixtures was evaluated by conducting draindown, moisture susceptibility test, aging test, rutting test, creep test, permeability test, and fatigue life tests. The PE fibers reinforce the binder system, resulting in the increase in the viscosity of the system. Draindown test results indicated that PE fibers can be effectively used as a stabilizer in SMA to retard draindown of binder and mineral filler. To study the behaviour of SMA mixtures with different additives, mixtures were designed by Marshall and Superpave. Results showed that mixtures designed by Superpave yielded in 0.2 % reduced asphalt content compared to mixtures designed by the Marshall method. From the present study, results indicated that mixtures prepared with PE fibers showed improved performance than reference SMA mixtures with cellulose fibers. Mixtures prepared with PEMB showed improved performance properties compared to mixtures with PE fibers and cellulose fibers.